A Phase III study shows that a 40mg/1mL dose of Teva's (TEVA) Copaxone given three times a week...

|About: Teva Pharmaceutical Indus... (TEVA)|By:, SA News Editor

A Phase III study shows that a 40mg/1mL dose of Teva's (TEVA) Copaxone given three times a week significantly reduces relapse rates at 12 months in patients with multiple sclerosis, and that the drug is safe and tolerable at this measurement. The current approved dose for Copaxone is 20mg/1mL once a day. (PR) Meanwhile, Teva has signed a five-year deal to commercialize Illumina's (ILMN) Verifi non-invasive pre-natal test in Israel. The test can identify chromosomal abnormalities in fetuses. (PR)